@ Vikas Sharma | Sr Journalist
New Delhi: Trivitron Healthcare Private Limited, a leading medical device company providing affordable healthcare solutions to the healthcare industry and Neuberg Diagnostics Private Limited, the fastest growing healthcare start-up in India, which ranks among the top 4 diagnostic service providers in India, today entered into a strategic partnership by signing a Memorandum of Association (MoU) with the Centre for Cellular And Molecular Platforms (C-CAMP), an initiative of the Department of Biotechnology, Ministry of Science and Technology and Earth Sciences, Govt. of India.
The MoU was signed in the presence of Dr. Renu Swarup, Secretary, Department of Biotechnology, Ministry of Science and Technology, Government of India & Chairperson, Biotechnology Industry Research Assistance Council (BIRAC); Dr. Taslimarif Saiyed, CEO & Director, C-CAMP; and Dr. G. S. K. Velu, Chairman & Managing Director, Trivitron Healthcare Private Limited & Neuberg Diagnostics Private Limited in presence of Dr. Sujay Ramaprasad, Medical Director, Neuberg Diagnostics Private Limited.
This partnership is a strategic step for both Trivitron and C-CAMP towards co-development of world-class healthcare technologies completely indigenously under “Joint Intellectual Properties” (i.e. product and process patents and know-how) aegis.
As part of the arrangement, Neuberg Anand Academy for Laboratory Medicine (NAALM) will partner with C-CAMP for technical training courses covering Flow Cytometry, Genomics, Mass Spectrometry and other advanced technology platforms. Also Neuberg Anand Reference Laboratory and Anand Diagnostic Laboratory – A Neuberg Associate will have access to high end technology like electron microscopy at C-CAMP for analytical testing and for research into method development.
C-CAMP has developed and tested an indigenous multiplex fluorescent microfluidic-analyser, covered under two patents; a base-patent for microfluidics flow analyser, which is filed and granted in several geographies, and a follow-on patent covering multiplex functionality. C-CAMP will demonstrate proof of concept and will participate in the co-development of a biological fluid analyser for clinical diagnostics. By the MoU, Trivitron which has a history of developing and installing diagnostic devices, including imaging devices globally is expected to facilitate these C-CAMP developed technologies in reaching a wider market segment commercially.